Trial · NCT01418001
Adverse events19
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 19 of 19
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Alanine aminotransferase increased | Blood and lymphatic system disorders | Level 1: Pazopanib 400 mg QD | 2 | 5 | |
| other | Anemia | Blood and lymphatic system disorders | Level 1: Pazopanib 400 mg QD | 4 | 5 | |
| other | Aspartate aminotransferase increased | Blood and lymphatic system disorders | Level 1: Pazopanib 400 mg QD | 1 | 5 | |
| other | Diarrhea | Gastrointestinal disorders | Level 1: Pazopanib 400 mg QD | 1 | 5 | |
| other | Fatigue | General disorders | Level 1: Pazopanib 400 mg QD | 2 | 5 | |
| other | Hoarseness | General disorders | Level 1: Pazopanib 400 mg QD | 1 | 5 | |
| other | Hyperglycemia | Metabolism and nutrition disorders | Level 1: Pazopanib 400 mg QD | 2 | 5 | |
| other | Hypertension | Cardiac disorders | Level 1: Pazopanib 400 mg QD | 1 | 5 | |
| other | Hypertriglyceridemia | Metabolism and nutrition disorders | Level 1: Pazopanib 400 mg QD | 2 | 5 | |
| other | Hypoalbuminemia | Metabolism and nutrition disorders | Level 1: Pazopanib 400 mg QD | 2 | 5 | |
| other | Hypocalcemia | Metabolism and nutrition disorders | Level 1: Pazopanib 400 mg QD | 2 | 5 | |
| other | Hyponatremia | Metabolism and nutrition disorders | Level 1: Pazopanib 400 mg QD | 1 | 5 | |
| other | Lymphocyte count decreased | Blood and lymphatic system disorders | Level 1: Pazopanib 400 mg QD | 2 | 5 | |
| other | Mucositis oral | General disorders | Level 1: Pazopanib 400 mg QD | 1 | 5 | |
| other | Nausea | Gastrointestinal disorders | Level 1: Pazopanib 400 mg QD | 1 | 5 | |
| other | Platelet count decreased | Blood and lymphatic system disorders | Level 1: Pazopanib 400 mg QD | 1 | 5 | |
| serious | Wound infection | Infections and infestations | Level 1: Pazopanib 400 mg QD | 1 | 5 | |
| serious | Fatigue | General disorders | Level 1: Pazopanib 400 mg QD | 1 | 5 | |
| serious | Alanine aminotransferase increased | Blood and lymphatic system disorders | Level 1: Pazopanib 400 mg QD | 1 | 5 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01418001/events